Levbid Tablets

Quick links to important sections

Levbid Tablets

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levbid Tablets

Levbid Tablets are a prescription-only medication classified primarily as an anticholinergic agent and a parasympatholytic. This specific formulation contains the active ingredient hyoscyamine, which is utilized for controlling involuntary muscle activity. The drug belongs to the class of tropane alkaloids, which modulate the involuntary signals sent through the autonomic nervous system. Unlike common skeletal muscle relaxants, this unique formulation focuses its action on smooth muscle tissues and secretory glands.

What Type of Medicine is Levbid Tablets?

Levbid Tablets is a single-ingredient antispasmodic agent. It is one of several commercial formulations of hyoscyamine, distinguished by its specific extended-release tablet form. The medication's pharmacological class is defined by its ability to cause cholinergic blockade, interrupting the nerve messenger acetylcholine, which is responsible for triggering muscle contraction and secretion in the internal organs. This means the core action is to block nerve signals that trigger spasms. This mechanism offers a targeted solution for controlling internal involuntary tension, such as the cramping that can occur in the intestines.

Levbid Tablets Composition and Extended-Release Form

The active ingredient in Levbid Tablets is hyoscyamine, a belladonna alkaloid used in pharmaceutical preparations. Hyoscyamine is delivered as an extended-release tablet for the oral route of administration, a key feature of the Levbid brand. This sustained-release dosage form is engineered to control the release of the active compound over several hours, aiming to maintain a more consistent therapeutic level than immediate-release formulations.

General Benefit of its Antispasmodic Action

The general benefit of taking Levbid is to achieve antispasmodic relief and reduction of glandular secretion across several body systems. By inhibiting parasympathetic signals, the medication decreases involuntary tension, alleviating the cramping, or spasms, of smooth muscles in various internal organs. Furthermore, its ability to act as an antisecretory agent helps to diminish fluid production, making its overall general purpose one of control over hyperactive internal muscle and glandular functions.

Regulatory References

  1. Hyoscyamine Monograph (NIH PubChem)
  2. Official Drug Label (DailyMed)

What side effects are possible with Levbid Tablets?

Possible Side Effects and Safety Information

The adverse reactions associated with Levbid Tablets, an anticholinergic agent, are generally considered manifestations of its pharmacological action and are documented in regulatory sources as dose-related and subject to individual variation. The safety profile is structured by the body systems affected, consistent with official reporting standards.

System-Organ Classifications of Adverse Effects

Adverse effects documented in regulatory sources predominantly reflect the drug's anticholinergic properties across several organ systems:

  • Eye Disorders: Reactions include blurred vision, mydriasis (pupil dilation), cycloplegia, and increased ocular tension.
  • Gastrointestinal Disorders: Effects span from dryness of the mouth, loss of taste, constipation, and bloated feeling to nausea and vomiting.
  • Nervous System and Psychiatric Disorders: Effects include headache, drowsiness, dizziness, fatigue, and insomnia. More pronounced central nervous system effects may involve hallucinations, short-term memory loss, speech disturbance, and mental confusion or excitement.
  • Cardiac Disorders: The medication is associated with tachycardia (increased heart rate) and palpitations.
  • Renal and Urinary Disorders: The drug may cause urinary hesitancy and retention.
  • Dermatologic and Other Effects: Decreased sweating is a documented effect. Allergic reactions, urticaria, and other dermal manifestations have also been reported, along with impotence and suppression of lactation.

Serious Safety Considerations and Special Populations

Official labeling defines specific circumstances and populations that require particular safety attention. Heat prostration, manifesting as fever and heat stroke, can occur due to the drug's effect of decreasing sweating when patients are exposed to high environmental temperatures. Acute central nervous system signs, such as psychosis, may also be reported, typically resolving within 12 to 48 hours after discontinuation of the drug. Older adults are noted as being especially susceptible to anticholinergic side effects, including confusion and urinary retention. Use is not recommended for children under twelve years of age.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose with Hyoscyamine as a severe extension of its pharmacological effects, necessitating immediate emergency action.

Documented Overdose Manifestations

Symptoms and clinical signs formally documented in prescribing information include headache, dizziness, and signs of CNS stimulation. Physical manifestations often involve blurred vision, dilated pupils (mydriasis), excessive dryness of the mouth, nausea, and vomiting. Overdose may also present with fever and hot dry skin due to effects on the thermoregulatory system.

Severe Outcomes and Emergency Response

Overdosage carries the risk of progression to severe, life-threatening outcomes, notably a curare-like effect which includes the potential for paralysis of the respiratory muscles and significant tachycardia. There is also a documented risk of heat stroke in high environmental temperatures.

Regulatory guidance mandates that patients seek emergency medical attention immediately if an overdose is suspected. Urgent medical services (e.g., calling 911) must be contacted if the individual collapses, has a seizure, has trouble breathing, or cannot be awakened.

Management and Specific Interventions

The management procedures documented in the official label include immediate lavage of the stomach and symptomatic treatment for fever, such as tepid water sponge baths. The agent Physostigmine is listed in regulatory documents as a potential pharmacological intervention for treating severe toxicity.

Population-Specific Considerations

Regulatory authorities note that infants and young children are especially susceptible to the toxic effects, and geriatric patients are also highly susceptible to severe anticholinergic effects like confusion.

Therapeutic Uses of Levbid Tablets

Levbid Tablets is applied across domains where additional symptomatic support is needed. The medication is used to help with symptom clusters that may become intense or disruptive. It is commonly used across conditions presenting with acute episodes and is considered relevant for easing symptoms that interfere with daily functioning. This includes applications for managing symptoms related to gastrointestinal issues, spastic bladder, and conditions marked by localized discomfort.

The core benefit is centered on easing the patient’s experience: “The treatment provides support that helps ease the overall symptom burden when symptoms become temporarily overwhelming.” It is often used when symptoms intensify and supportive relief is needed, supporting the patient during difficult episodes by easing distress and contributing to improved comfort during periods of heightened symptoms. This helps patients cope more steadily with symptom fluctuations, maintaining a sense of stability when symptoms are more noticeable.

Quick Fact: Symptomatic Support for Spasms and Discomfort Levbid is applicable within clinical settings that involve acute or disruptive symptom patterns linked to organ-specific functional stress.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Population Eligibility Rules for Levbid Tablets

Official regulatory documents define strict criteria for the use of Levbid Tablets (Hyoscyamine Sulfate Extended-Release), classifying populations as eligible, restricted, or strictly prohibited from use.

Absolute Contraindications (Prohibited Use)

The medicine is contraindicated and must not be used by patients diagnosed with specific obstructive or debilitating conditions, including glaucoma, obstructive uropathy, and obstructive diseases of the gastrointestinal tract (such as paralytic ileus, severe ulcerative colitis, or toxic megacolon). Contraindication also applies to individuals with myasthenia gravis, myocardial ischemia, unstable cardiovascular status in acute hemorrhage, or known hypersensitivity to belladonna alkaloids.

Age and Conditional Use

Population Regulatory Status
Children under 12 Not recommended for this extended-release formulation.
Adults and Adolescents (12+) Eligible under standard labeled conditions.
Elderly Patients Requires cautious dose selection due to increased susceptibility to effects and reduced renal function.
Pregnancy Category C. Use is only permitted if clearly needed.
Lactation Should not be administered to a nursing mother.

Use of the medication requires extreme caution in populations with conditions like renal disease, coronary heart disease, or autonomic neuropathy.

What should I know about interactions with other medicines?

The official regulatory profile for Levbid Tablets is structured around two key interaction domains: pharmacodynamic enhancement and pharmacokinetic interference.

The most significant interaction involves pharmacodynamic enhancement of cholinergic blockade, which may result in additive adverse effects when co-administered with other anticholinergic agents. This includes product classes such as other antimuscarinics, tricyclic antidepressants, Monoamine Oxidase (MAO) inhibitors, Phenothiazines, and certain Antihistamines, along with specific medicines like Amantadine and Haloperidol.

The second domain, pharmacokinetic interference, involves a decrease in the absorption and exposure of other oral medications due to the reduction in gastrointestinal motility caused by Levbid. This includes substances such as oral potassium chloride and certain adsorbent antidiarrheals. To prevent interference with the absorption of hyoscyamine itself, a mandatory timing separation is officially required for antacids; Levbid must be administered before meals, while antacids must be taken after meals.

A specific substance interaction is documented with alcohol, where co-administration may increase the risk of drowsiness and dizziness. Furthermore, a population-specific interaction caution is noted: because the drug is substantially excreted by the kidney, the risk of toxic reactions may be greater for elderly patients who have impaired renal function.

Mechanism of Action

Levbid Tablets contain the compound hyoscyamine, a muscarinic acetylcholine receptor antagonist. Hyoscyamine acts by competitively and non-selectively binding to muscarinic acetylcholine receptors (M1 through M5) located on autonomic effector cells, including smooth muscle, exocrine glands, and cardiac muscle.

At the cellular level, this interaction prevents the endogenous neurotransmitter acetylcholine from binding and activating these receptors. In smooth muscle cells, particularly within the gastrointestinal tract, the antagonism of muscarinic receptors halts the acetylcholine-mediated downstream signaling cascade, which includes G-protein activation and subsequent changes in intracellular calcium concentration. The inhibition of this cholinergic signaling leads to a reduction in smooth muscle contraction and a decrease in propulsive motility (peristalsis).

Concurrently, the antagonism at receptors on exocrine glands (e.g., salivary, gastric, sweat) diminishes secretomotor nerve stimulation, resulting in decreased secretion of bodily fluids. In the heart, muscarinic receptor blockade modulates the activity of the sinoatrial (SA) and atrioventricular (AV) nodes, leading to altered cardiac conduction and rate.

Dosage and Administration Information

Levbid extended-release tablets (0.375 mg) are administered exclusively via the oral route. The official administration protocol is standardized to utilize the sustained-release nature of the tablet, which is designed to provide consistent systemic availability over time.


Official Administration Protocol

The standard frequency for adults and pediatric patients aged 12 years and older is one to two tablets every 12 hours (b.i.d.). This 12-hour interval is the primary schedule for the extended-release formulation. Under specific circumstances, the dosage may be adjusted to one tablet every 8 hours, but the total intake must not exceed 1.5 mg (four tablets) within a 24-hour period.

Intake Requirements and Handling

To ensure the correct function of the sustained-release mechanism, the tablets must be swallowed whole and must not be crushed or chewed. The official instructions specify taking the medication 30 minutes to one hour before meals to manage absorption conditions. A practical procedural detail is that the non-eroding tablet matrix may appear in the stool, which is part of the drug delivery system.

For older adults, the official use protocol includes a specific procedural caution: dose selection should be conservative, often initiating treatment at the lowest end of the effective dosing range, due to potential increased patient sensitivity to the usual adult dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Levbid Tablets

The evidence supporting the evaluation of Levbid Tablets (Hyoscyamine) is found in clinical research and historical scientific literature used in research exploring how the medication may influence symptoms related to internal muscle spasms and excessive secretions. Research was studied for defined clinical conditions and uses neutral, evidence-appropriate verbs to describe what has been observed in study populations.


Evidence for Use in Gastrointestinal Spasm and Hypermotility

Levbid Tablets was studied in research contexts exploring the adjunctive use in conditions characterized by fluctuating or episodic manifestations, particularly in the gastrointestinal (GI) tract. Research has examined its use in people diagnosed with Irritable Bowel Syndrome (IBS) and other conditions characterized by involuntary GI spasms.

Studies explored how the medicine was associated with changes in patient-reported outcomes describing perceived discomfort. Researchers used short-term Randomized Controlled Trials (RCTs) and systematic reviews applied in studies examining episodic symptom patterns of abdominal pain and cramping severity. These studies monitored outcomes related to physical discomfort over defined time intervals. Findings indicate short-term patterns observed in the studies where measurements of symptom scores were collected.


Evidence Gaps and Areas of Uncertainty

The research highlights what is known—and what is still uncertain—about this medication. One major area of uncertainty is the limited availability of comparative evidence between the extended-release Hyoscyamine formulation and newer drug classes that are now the primary treatment options for many conditions like IBS. The available data remain limited for specific patient groups, particularly for children and adolescents.

Long-term effects are not fully established for the extended-release formulation of Levbid Tablets, as follow-up durations were limited across the core efficacy trials. Research provides context on group patterns, not personal outcomes, and highlights that the existing evidence base is often insufficient to draw definitive conclusions regarding long-term management or optimal use in all subgroups.

Key Studies & References

  1. Hyoscyamine Sulfate Extended-Release Tablets: Package Insert / Prescribing Info (DailyMed)
  2. Hyoscyamine: MedlinePlus Drug Information
  3. Sublingual hyoscyamine sulfate in combination with ketorolac tromethamine for ureteral colic: a randomized, double-blind, controlled trial

Frequently Asked Questions (FAQ)

Common questions about Levbid Tablets (FAQ)


Q: Is Levbid Tablets the same kind of drug as Bentyl or other similar medicines?

Levbid contains the active ingredient hyoscyamine sulfate, which is classified as an anticholinergic and antispasmodic agent. According to official product information, this is the same general drug class as dicyclomine (Bentyl). These medicines share a similar fundamental action: blocking certain nerve signals to relax muscles and reduce secretions.


Q: Are there any severe side effects I should be aware of with Levbid Tablets?

Official labeling documents the potential for serious effects linked to this class of medication. These can include psychosis (marked by confusion or hallucinations), heat prostration (a form of heat stroke), difficulty passing urine, and changes in heart rhythm such as a fast or irregular heartbeat. Patients can review the product information regarding these potential effects.


Q: Is Levbid Tablets appropriate for older adults (seniors)?

Official product information notes that dose selection for older adults is typically conservative and cautious, reflecting their potential for increased sensitivity to the medication's effects. Seniors are noted to be especially susceptible to specific anticholinergic side effects such as confusion and urinary retention.


Q: Can teenagers or young adults use Levbid Tablets?

The extended-release tablet formulation is generally not recommended for children under 12 years of age. Official documents indicate that use in adolescents aged 12 and older is generally permitted under standard labeled conditions.


Q: Is Levbid Tablets safe for people with certain kidney conditions?

The product information states that this medication is largely processed and excreted by the kidneys. Official information indicates that the drug is used with caution in patients with renal disease because impaired kidney function can increase the risk of toxic reactions.


Q: What if I experience unusual sweating while taking Levbid Tablets?

The official documentation confirms that this medication may decrease sweating as one of its known effects. This decreased ability to sweat can be risky and may lead to a condition called heat prostration (fever and heat stroke) if a person is exposed to high temperatures or engages in strenuous activity.


Q: Are there different forms of Levbid Tablets available, like a generic version?

Levbid is a brand name for the active ingredient hyoscyamine sulfate. According to official information, this active ingredient is available in many different formulations and is generally accessible as a generic formulation.


Q: Does Levbid Tablets affect the central nervous system?

Yes, official labeling confirms the drug can affect the central nervous system (CNS). Reported CNS signs include drowsiness, dizziness, confusion, disorientation, and short-term memory loss. More pronounced effects like hallucinations have also been noted.


Q: Is Levbid Tablets considered a fast-acting or slow-acting medication?

Levbid is manufactured as an extended-release or sustained-release tablet. This formulation is designed to release the medication slowly and consistently over time, typically 12 hours, providing a prolonged effect rather than an immediate or fast-acting one.


Q: What if I have an allergic reaction to Levbid Tablets?

The drug is contraindicated (should not be used) if a patient has a known hypersensitivity to belladonna alkaloids. If serious symptoms like a rash, swelling, or trouble breathing occur, it may be necessary to seek medical attention.


Q: What is Levbid Tablets used for, besides the main approved use?

Official documentation indicates that besides its use in intestinal disorders like IBS, the drug is also indicated for symptomatic relief of spasms related to biliary and renal colic. Furthermore, it is indicated as a drying agent in certain respiratory conditions and as an additional therapy for peptic ulcer.


Q: How long does it typically take for Levbid Tablets to start working?

The specific onset of action for the extended-release tablet is not uniformly documented in the patient labeling. However, information about immediate-release forms are described as acting rapidly, often within minutes, after absorption.


Q: What happens if I forget to take a Levbid Tablet?

The official product labeling generally does not provide instructions for handling a missed dose. Regulatory guidelines recommend that the medication be taken exactly as prescribed by the healthcare provider.


Q: Why are people given Levbid Tablets before certain medical procedures?

The drug's documented actions include the ability to control excessive pharyngeal, tracheal, and bronchial secretions and relax smooth muscle. These effects are sometimes desired during patient preparation for certain diagnostic or surgical procedures.


Q: Is it possible to develop a tolerance to Levbid Tablets over time?

The official labeling does not specifically use the term tolerance. However, it does note that the prolonged use of anticholinergic drugs may decrease or inhibit salivary flow, which could potentially lead to dental issues.


Q: Does Levbid Tablets have a warning about driving or operating machinery?

Yes. The product information states that engaging in activities requiring mental alertness, such as operating a motor vehicle or heavy machinery, is not recommended. This is due to the potential for side effects like drowsiness, dizziness, or blurred vision.


Q: Can Levbid Tablets be used for stomach flu or temporary digestive upset?

The label states the drug is indicated for symptoms of mild dysenteries and acute intestinal inflammation. However, diarrhea can be an early sign of a serious condition like intestinal obstruction, which is a contraindication for this drug. Use requires careful evaluation.


Q: What are the typical ingredients found in Levbid Tablets besides the active drug?

In addition to the active ingredient, hyoscyamine sulfate, official labeling lists inactive ingredients (excipients) for the extended-release tablet. These typically include calcium phosphate dibasic, ethylcellulose, lactose monohydrate, magnesium stearate (veg.), microcrystalline cellulose, and stearic acid.


Q: What should I do if I suspect an interaction between Levbid Tablets and another medicine?

Official labeling advises that if a patient experiences serious side effects that could be linked to an interaction, such as confusion, a fast heartbeat, or eye pain, it is recommended to seek medical attention if serious side effects are suspected.


Q: Is there a maximum amount of time Levbid Tablets is usually prescribed for?

No maximum duration of use is formally stated in the labeling. It is noted that while no long-term studies have been performed to assess cancer risk, 40 years of marketing experience shows no demonstrable evidence of such a problem.


Q: Can I take Levbid Tablets if I'm preparing for a colonoscopy or other procedure?

The drug’s actions of reducing secretions and slowing gastrointestinal movement are often utilized in preparing for diagnostic procedures. However, the official label does not explicitly name colonoscopy or provide procedural instructions for its use.


Q: Does Levbid Tablets affect blood pressure?

While the drug primarily affects heart rate (it can cause tachycardia), the official labeling lists precautions for use in patients with hypertension (high blood pressure) and those with unstable cardiovascular status, implying relevance to blood pressure regulation.


Q: Is there an official patient leaflet available for Levbid Tablets?

Yes, the drug is distributed with FDA-approved labeling that contains a section titled Information for Patients. This document is publicly accessible through authoritative resources such as DailyMed and MedlinePlus.

How should Levbid Tablets be stored and disposed of?

Storing and Disposing of Levbid Extended-Release Tablets

Levbid tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted brief excursions up to 30 C (86 F).

  • Protection: The medication must be kept in a tight, light-resistant container and protected from excessive heat and moisture. It should not be stored in high-humidity areas, such as a bathroom.
  • Child Safety: It is mandatory to keep Levbid tablets out of the reach of children using the child-resistant closure and storing the bottle in a safe location.
  • Disposal: Unused or expired tablets should be thrown away according to official guidelines. They must not be flushed down the toilet or poured down a drain. The preferred method for disposal is utilizing a local drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Levbid Tablets found in:

A-Z Index: